Genetic polymorphisms of interleukin-10 and transforming growth factor-β1 and antituberculosis drugs-induced liver injury

Jung, Sodam; Kim, Sang-Hoon; Sohn, Jang Won; Yoon, Ho Joo; Shin, Dong Ho; Jee, Young-Koo; Kim, Sang-Heon

doi:10.4168/aard.2017.5.1.41

Original Article

Open Access


Allergy Asthma Respir Dis. 2017 Jan;5(1):41-46. Korean. Published online Jan 31, 2017. https://doi.org/10.4168/aard.2017.5.1.41
© 2017 The Korean Academy of Pediatric Allergy and Respiratory Disease; The Korean Academy of Asthma, Allergy and Clinical Immunology


Genetic polymorphisms of interleukin-10 and transforming growth factor-β1 and antituberculosis drugs-induced liver injury
Sodam Jung,¹ Sang-Hoon Kim,² Jang Won Sohn,¹ Ho Joo Yoon,¹ Dong Ho Shin,¹ Young-Koo Jee,³ and Sang-Heon Kim¹
¹Department of Internal Medicine, Hanyang University College of Medicine, Seoul, Korea.
²Department of Internal Medicine, Eulji University School of Medicine, Seoul, Korea.
³Department of Internal Medicine, Dankook University College of Medicine, Cheonan, Korea.
Correspondence to: Sang-Heon Kim. Department of Internal Medicine, Hanyang University College of Medicine, 222 Wangsimni-ro, Seongdong-gu, Seoul 04763, Korea. Tel: +82-2-2290-8336, Fax: +82-2-2298-9183, Email: sangheonkim@hanyang.ac.kr

Received October 09, 2016; Revised October 27, 2016; Accepted November 22, 2016.
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/).

Go to: Abstract
Purpose Drug-induced liver injury is one of the serious adverse reactions resulting in severe morbidity and discontinuation of medications. Previously, IL-10 gene polymorphism has been reported to be associated with diclofenac-induced hepatitis. In this study, we aimed to investigate the associations between genetic polymorphisms of immune-regulating cytokines (IL-10 and TGF-β1) with antituberculosis drugs (ATD)-induced liver injury. Methods We enrolled 80 patients with ATD-induced liver injury and 238 ATD-tolerant controls. Two single nucleotide polymorphisms (SNP) of IL-10 (-1082A>G, rs1800896; -819T>C, rs1800871) and one promoter SNP of TGF-β1 gene (-509C>T, rs1800469) were genotyped in both groups. Genotype frequencies of these SNPs were compared between case and control groups. Results In 2 promoter SNPs of IL-10 gene, there was no significant difference of genotype frequencies between patients with ATD-induced liver injury and controls. In addition, the genotype frequency of TGF-β1 -509C>T SNP in ATD-induced liver injury patients were not different from those of controls. Conclusion In conclusion, there was no significant association between IL-10 and TGF-β1 gene polymorphisms and ATD-induced liver injury. These findings suggest that IL-10 and TGF-β1 do not play important role in the development of ATD-induced liver injury.


Keywords: Antitubercular agents; Drug-induced liver injury; Interleukin-10; Transforming growth factor beta1; Genetic polymorphism

Go to:

Tables


	Table 1 Single nucleotide polymorphisms tested in this study
	Click for larger imageClick for full tableDownload as Excel file


	Table 2 Clinical characteristics of the study subjects
	Click for larger imageClick for full tableDownload as Excel file


	Table 3 Comparisons of the genotype frequencies between ATD-induced liver injury and ATD-tolerant controls
	Click for larger imageClick for full tableDownload as Excel file


	Table 4 Associations of immune related genes with ATD-induced liver injury
	Click for larger imageClick for full tableDownload as Excel file

Go to:

Notes

This research was supported by a grant of the Korea Health Technology R&D Project through the Korea Health Industry Development Institute (KHIDI), funded by the Ministry of Health & Welfare, Republic of Korea (grant number : HI15C1234).

Go to:

References


1.	Blumberg HM, Burman WJ, Chaisson RE, Daley CL, Etkind SC, Friedman LN, et al. American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America: treatment of tuberculosis. Am J Respir Crit Care Med 2003;167:603–662.

2.	Tahaoğlu K, Ataç G, Sevim T, Tärün T, Yazicioğlu O, Horzum G, et al. The management of anti-tuberculosis drug-induced hepatotoxicity. Int J Tuberc Lung Dis 2001;5:65–69.

3.	Reuben A, Koch DG, Lee WM, Acute Liver Failure Study GroupDrug-induced acute liver failure: results of a U.S. multicenter, prospective study. Hepatology 2010;52:2065–2076.

4.	Kwon H, Lee SH, Kim SE, Lee JH, Jee YK, Kang HR, et al. Spontaneously reported hepatic adverse drug events in Korea: multicenter study. J Korean Med Sci 2012;27:268–273.

5.	Tostmann A, Boeree MJ, Aarnoutse RE, de Lange WC, van der Ven AJ, Dekhuijzen R. Antituberculosis drug-induced hepatotoxicity: concise up-to-date review. J Gastroenterol Hepatol 2008;23:192–202.

6.	Huang YS. Recent progress in genetic variation and risk of antituberculosis drug-induced liver injury. J Chin Med Assoc 2014;77:169–173.

7.	Kim SH, Kim SH, Bahn JW, Kim YK, Chang YS, Shin ES, et al. Genetic polymorphisms of drug-metabolizing enzymes and anti-TB drug-induced hepatitis. Pharmacogenomics 2009;10:1767–1779.

8.	Uetrecht J. Immunoallergic drug-induced liver injury in humans. Semin Liver Dis 2009;29:383–392.

9.	Aithal GP. Pharmacogenetic testing in idiosyncratic drug-induced liver injury: current role in clinical practice. Liver Int 2015;35:1801–1808.

*10.*	Aithal GP, Ramsay L, Daly AK, Sonchit N, Leathart JB, Alexander G, et al. Hepatic adducts, circulating antibodies, and cytokine polymorphisms in patients with diclofenac hepatotoxicity. Hepatology 2004;39:1430–1440.

*11.*	Pachkoria K, Lucena MI, Crespo E, Ruiz-Cabello F, Lopez-Ortega S, Fernandez MA, et al. Analysis of IL-10, IL-4 and TNF-alpha polymorphisms in drug-induced liver injury (DILI) and its outcome. J Hepatol 2008;49:107–114.

*12.*	Kim SH, Kim SH, Yoon HJ, Shin DH, Park SS, Kim YS, et al. TNF-α genetic polymorphism -308G/A and antituberculosis drug-induced hepatitis. Liver Int 2012;32:809–814.

*13.*	Saukkonen JJ, Cohn DL, Jasmer RM, Schenker S, Jereb JA, Nolan CM, et al. An official ATS statement: hepatotoxicity of antituberculosis therapy. Am J Respir Crit Care Med 2006;174:935–952.

*14.*	Metushi IG, Cai P, Zhu X, Nakagawa T, Uetrecht JP. A fresh look at the mechanism of isoniazid-induced hepatotoxicity. Clin Pharmacol Ther 2011;89:911–914.

*15.*	Metushi IG, Zhu X, Chen X, Gardam MA, Uetrecht J. Mild isoniazid-induced liver injury in humans is associated with an increase in Th17 cells and T cells producing IL-10. Chem Res Toxicol 2014;27:683–689.

*16.*	Perwitasari DA, Atthobari J, Wilffert B. Pharmacogenetics of isoniazid-induced hepatotoxicity. Drug Metab Rev 2015;47:222–228.

*17.*	Sharma SK, Balamurugan A, Saha PK, Pandey RM, Mehra NK. Evaluation of clinical and immunogenetic risk factors for the development of hepatotoxicity during antituberculosis treatment. Am J Respir Crit Care Med 2002;166:916–919.

*18.*	Chen R, Zhang Y, Tang S, Lv X, Wu S, Sun F, et al. The association between HLA-DQB1 polymorphism and antituberculosis drug-induced liver injury: a Case-Control Study. J Clin Pharm Ther 2015;40:110–115.

*19.*	Wang J, Chen R, Tang S, Lv X, Wu S, Zhang Y, et al. Analysis of IL-6, STAT3 and HSPA1L gene polymorphisms in anti-tuberculosis drug-induced hepatitis in a nested case-control study. PLoS One 2015;10:e0118862.

*20.*	de Waal Malefyt R, Yssel H, Roncarolo MG, Spits H, de Vries JE. Interleukin-10. Curr Opin Immunol 1992;4:314–320.

*21.*	Nelson DR, Lauwers GY, Lau JY, Davis GL. Interleukin 10 treatment reduces fibrosis in patients with chronic hepatitis C: a pilot trial of interferon nonresponders. Gastroenterology 2000;118:655–660.

*22.*	Perrey C, Turner SJ, Pravica V, Howell WM, Hutchinson IV. ARMS-PCR methodologies to determine IL-10, TNF-alpha, TNF-beta and TGF-beta 1 gene polymorphisms. Transpl Immunol 1999;7:127–128.

*23.*	Turner DM, Williams DM, Sankaran D, Lazarus M, Sinnott PJ, Hutchinson IV. An investigation of polymorphism in the interleukin-10 gene promoter. Eur J Immunogenet 1997;24:1–8.

*24.*	Ouyang L, Lv YD, Hou C, Wu GB, He ZH. Quantitative analysis of the association between interleukin-10 1082A/G polymorphism and susceptibility to sepsis. Mol Biol Rep 2013;40:4327–4332.

*25.*	Cai F, Cui N, Ma H, Wang X, Qiao G, Liu D. Interleukin-10 -1082A/G polymorphism is associated with the development of acute pancreatitis in a Chinese population. Int J Clin Exp Pathol 2015;8:15170–15176.

*26.*	Wang J, Chen R, Tang S, Lv X, Wu S, Zhang Y, et al. Interleukin-4 and interleukin-10 polymorphisms and antituberculosis drug-induced hepatotoxicity in Chinese population. J Clin Pharm Ther 2015;40:186–191.

*27.*	Michalopoulos GK. Liver regeneration: molecular mechanisms of growth control. FASEB J 1990;4:176–187.

*28.*	Blobe GC, Schiemann WP, Lodish HF. Role of transforming growth factor beta in human disease. N Engl J Med 2000;342:1350–1358.

*29.*	Border WA, Noble NA. Transforming growth factor beta in tissue fibrosis. N Engl J Med 1994;331:1286–1292.

*30.*	Friedman SL. Seminars in medicine of the Beth Israel Hospital, Boston. The cellular basis of hepatic fibrosis. Mechanisms and treatment strategies. N Engl J Med 1993;328:1828–1835.

*31.*	Mohy A, Fouad A. Role of transforming growth factor-β1 in serum and -509 C>T promoter gene polymorphism in development of liver cirrhosis in Egyptian patients. Meta Gene 2014;2:631–637.

*32.*	Xiang TX, Cheng N, Li XN, Wu XP. Association between transforming growth factor-β1 polymorphisms and hepatocellular cancer risk: a meta-analysis. Hepatol Res 2012;42:583–590.

*33.*	Park HW. Interpretation of negative results in genetic epidemiology. Allergy Asthma Respir Dis 2015;3:93–94.